MAPT and Alzheimer disease: Plasma p-tau231 has been recently proposed as a potential blood-based biomarker of emerging AD pathology with clinical utility as a rapid screening test, and in clinical trials to targeting vulnerable population under the threshold of Aβ positivity and early tau deposition.